ProKidney Corp. - Asset Resilience Ratio
ProKidney Corp. (PROK) has an Asset Resilience Ratio of 50.17% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of ProKidney Corp. for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2024)
This chart shows how ProKidney Corp.'s Asset Resilience Ratio has changed over time. See PROK total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down ProKidney Corp.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ProKidney Corp. stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $176.40 Million | 50.17% |
| Total Liquid Assets | $176.40 Million | 50.17% |
Asset Resilience Insights
- Very High Liquidity: ProKidney Corp. maintains exceptional liquid asset reserves at 50.17% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ProKidney Corp. Industry Peers by Asset Resilience Ratio
Compare ProKidney Corp.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for ProKidney Corp. (2022–2024)
The table below shows the annual Asset Resilience Ratio data for ProKidney Corp..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 58.76% | $259.17 Million | $441.07 Million | -13.12pp |
| 2023-12-31 | 71.88% | $302.30 Million | $420.55 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $518.00 Million | -- |
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryo… Read more